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ABSTRACT
Purpose: Access to genomic tumor material is required to select patients for 
targeted therapies. However, tissue biopsies are not always feasible and therefore 
circulating cell-free DNA (cfDNA) has emerged as an alternative. Here we investigate 
the utility of cfDNA for genomic tumor profiling in the phase I setting.
Study design: Peripheral blood was collected from patients with advanced solid 
cancers eligible for phase I treatment. Patients failing the initial tissue biopsy due 
to inaccessible lesions or insufficient tumor cellularity (<10%) were included in the 
study. Genomic profiling of cfDNA including whole exome sequencing (WES) and 
somatic copy number alterations (SCNAs) analysis (OncoScan).
Results: Plasma cfDNA was pro- and retrospectively profiled from 24 and 20 
patients, respectively. The median turnaround time was 29 days (N= 24, range 13-
87 days) compared to tissue re-analyses of median 60 days (N= 6, range 29-98). 
Selected cancer-associated alterations (SCAAs) were identified in 70% (31/44) of 
patients, predominantly by WES due to the low sensitivity of OncoScan on cfDNA. 
Primarily, inaccessible cases of prostate and lung cancers could benefit from cfDNA 
profiling. In contrast, breast cancer patients showed a low level of tumor-specific 
cfDNA which might be due to cancer type and/or active treatment at the time of 
plasma collection.
Conclusion: Plasma cfDNA profiling using WES is feasible within a clinically 
relevant timeframe and represents an alternative to invasive tissue biopsies to identify 
possible treatment targets. Especially, difficult-to-biopsy cancers can benefit from 
cfDNA profiling, but tumor tissue remains the gold standard for molecular analyses.
INTRODUCTION
Knowledge of the genomic makeup of tumors is 
essential for cancer diagnosis, prognosis, and selection 
of treatment. With the great advancements in the field 
of precision medicine, genotype-directed therapy is 
becoming a standard tool for stratification of oncological 
patients. For instance, HER2 gene expression and EGFR 
mutation status are used to guide treatment for breast 
and non-small cell lung cancers (NSCLC), respectively 
[1, 2]. Ideally, fresh tissue is used to characterize the 
tumor but often archival material such as formalin-fixed 
paraffin-embedded (FFPE) tissue is used introducing 
several problems. First, archival tissue might not represent 
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the current malignancy due to clonal evolution of the 
disease over time and in response to previous therapies 
[3, 4]. Second, DNA from FFPE tissue are often highly 
fragmented influencing downstream analyses [5, 6]. 
Although tissue biopsies, either fresh or archival, represent 
standard for molecular testing, poor quality or inadequate 
quantity of tissue and DNA is often challenging besides 
the discomfort and risks of complications related to biopsy 
procedures. In NSCLC, tissue biopsies are unusable 
in 20-30% of patients [7], highlighting the need for an 
alternative source of tumor material.
Circulating cell-free DNA (cfDNA) has been 
widely investigated as a potential surrogate for tissue 
biopsies for non-invasive assessment of tumor-related 
genomic alterations as circulating tumor DNA (ctDNA) 
can be identified in cfDNA. Recently, FDA approved 
EGFR-mutation testing based on cfDNA for treatment 
stratification of NSCLC [8]. Due to the rapid development 
of NGS technology, it is now possible to characterize 
the molecular profile of cfDNA [9, 10] but no previous 
studies have investigated comprehensive cfDNA profiling 
in a prospective setting. The focus of whole exome 
sequencing (WES) studies has been on characterizing 
tumor heterogeneity and resistance [11, 12] and only 
few prospective studies have included cfDNA analyses, 
focusing mainly on treatment monitoring using small gene-
panels [13]. In a prospective study, Kaisaki et al., showed 
that targeted-sequencing of cfDNA in early stage lung 
cancers, was a valuable alternative to tissue in a diagnostic 
setting due to high concordance of tumor mutations 
between tissue and cfDNA [14]. Little has been reported 
on turnaround time of cfDNA analyses in a prospective 
setting, but results from retrospective cohorts have 
reported analysis times between 10-15 days [10, 15, 16]. 
Furthermore, studies characterizing somatic copy number 
alterations (SCNAs) in cfDNA have been sparse [17].
We performed a feasibility study including a pro- 
and retrospective cohort of patients eligible for phase I 
treatment where tissue was inaccessible for biopsy or the 
biopsy was too low in tumor cell content. Genomic cfDNA 
profiling included WES and SCNAs analyses (OncoScan). 
The aim of the study, was to investigate whether tumor-
specific DNA alterations could be identified in plasma 
cfDNA and whether the analysis could be performed 
within a time frame relevant in a clinical setting.
RESULTS
Patient characteristics
A total of 118 advanced cancer patients were 
prospectively enrolled in the CoPPO project from January 
to August 2018 (Figure 1). Of these, 24 patients (17%) 
underwent cfDNA analysis either because the tumor tissue 
was inaccessible for biopsy (N=9, Cohort 1) or the obtained 
tissue biopsy had low tumor cellularity (N= 15, Cohort 2). 
Various cancer types were included, the most represented 
being colorectal (N=5) and prostate cancer (N=4) (Table 
1). Six patients had subsequently a successful re-biopsy 
performed and three cases had archival FFPE tissue 
analyzed. Twenty patients were included in a retrospective 
cohort (Cohort 3), selected from the total CoPPO cohort as 
illustrated in Supplementary Figure 1. Eight patients from 
Cohort 3 were re-biopsied and genomic reports on tumor 
tissue were obtained. Across cohorts, an equal distribution 
of males (50%) and females (50%) were included and 41% 
(18/44) of the patients received treatment at the time of 
plasma collection (Supplementary Table 1). Furthermore, 
most patients had multiple metastatic sites with the most 
common biopsy site being liver, representing 67% (22/33) 
of the biopsy sites (Supplementary Table 1). Radiological 
assessment of the overall tumor burden was not available 
at the time of plasma sampling. Assessment of overall 
tumor burden is not a standard procedure in the CoPPO 
study and would not impact the enrollment of patients.
Feasibility of genomic cfDNA profiling
Method efficacy
Cell-free DNA was successfully extracted from 
all prospectively enrolled patients with concentrations 
ranging from 1.5 to 120 ng/ml plasma (median 8.0 ng/
ml) (Supplementary Table 2). The retrospective cohort 
was selected based on available cfDNA (Supplementary 
Figure 1) with concentrations from 2.2 to 181.5 ng/
ml plasma (median 26.2 ng/ml) (Supplementary Table 
2). Whole exome sequencing was performed on all 
patients (N=44) with a median overall average coverage 
of 186x (interquartile range IQR=273; Q1=90.80; 
Q3=364.30) and median 10x coverage on 94% of the 
exome (interquartile range IQR=0.0135; Q1=0.9344; 
Q3=0.9479) (Supplementary Figure 2 and Supplementary 
Table 2), similar to previous studies [18, 19].
OncoScan array used varying cfDNA input 
concentrations (≥ 5 ng) depending on the amount 
remaining after WES analysis (Supplementary Table 2). 
The median input was 20 ng cfDNA (range 7-80 ng). The 
OncoScan analysis was achieved on 40 out of 44 patients, 
as four samples had insufficient input material for full 
genomic profiling and therefore WES was prioritized. Of 
the 40 samples, 8 samples failed the analysis due to quality 
issues of either cfDNA (N= 1, P42) or OncoScan array (N= 
7, “Failed (suboptimal quality)” in Supplementary Table 
4). Noticeably, cfDNA concentration or input amount did 
not seem to affect ctDNA detection by OncoScan or WES 
although the small sample size could influence this result 
(P>0.05, t-test, unequal variance).
Turnaround time
The median turnaround time for cfDNA profiling 
in Cohort 1 and 2 was 29 days (range 13-87 days), 
defined as the median time from failed tissue biopsy 
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until the genomic report was completed (Supplementary 
Figure 3). The analysis time decreased and stabilized 
during the study due to improvement and establishment 
of the cfDNA workup. A fresh tissue re-biopsy was 
obtained and successfully profiled for six patients in the 
prospective cohorts. The median turnaround time was 60 
days (range 29-98) defined as the time from failed biopsy 
until completion of the genomic report on the re-biopsy 
(Supplementary Figure 3). Of note, inclusion of patients in 
Cohort 1, where no biopsy could be obtained, commenced 
after the initial tests of the cfDNA pipeline.
Detection of genomic tumor alterations in cfDNA
A complete genomic cfDNA report including 
both WES and OncoScan (+/- SCAA) was achieved in 
32/44 cases (Figure 2). Whole exome sequencing was 
successfully performed in all 44 cases and at least one 
SCAA was identified in 68% (30/44 patients) of patients. 
The most frequently altered genes were TP53 (N=14), 
APC (N=9), KRAS (N=4), ATR (N=14) and PIK3CA (N=3) 
(Figure 2A and Supplementary Table 3). A range of 30 
different SCAAs was observed only once (N=1). In 32% 
Table 1: Patient characteristics
Characteristic Prospective Cohorts 1+2 
(N= 24)
Retrospective Cohort 3  
(N= 20)
All patients  
(N= 44)
Age (median, range) 62 (36 – 82) 64 (26 – 75) 64 (26 – 82)
Gender
Male 12 10 22 (50%)
Female 12 10 22 (50%)
Tumor origin
Colorectal 5 10 15
Breast 3 5 8
Prostate 4 1 5
Endometrial 2 0 2
Head and neck 1 1 2
Bile duct 1 2 3
Lung (NSCLC) 3 0 3
Ovarian 1 0 1
OtherA 4 1 5
Cohorts
1 (Prospective, no biopsy) 9 - -
2 (Prospective, failed biopsy) 15 - -
3 (Retrospective) - 20 -
Number of patients with ≥ 
1 SCAAB 21 (88%) 10 (50%) 31 (70%)
Turnaround time (days)
cfDNA, N= 24 (median, 
range) 29 (13-87) - -
Tissue, N= 6 (median, range) 60 (29-98) - -
Profiling on other materials
Tissue re-biopsy 6 8 14
Archival FFPE tissue 3 0 3
AIncluded: Mesothelioma N=1, Testicular N=1, Pancreatic N=1, Gastric N= 1, Cervical N=1
BSCAA: Selected cancer-associated alterations
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(14/44 patients), WES did not detect a SCAA with almost 
half of these being breast cancers including a large fraction 
of patients in active treatment at the time of blood collection 
(Figure 3). Significantly more breast cancers were observed 
in the -SCAA group compared to the +SCAA group from 
either WES or OncoScan (P= 0.0048, Firsher’s exact test), 
whereas the fractions in treatment were not significantly 
different between the two SCAA-groups (P= 0.098, 
Firsher’s exact test). OncoScan array was successfully 
performed on 32/44 samples with acceptable quality 
values, with 43% (N=19) showing a silent chromosomal 
profile and 30% (N=13/44) with detectable SCAAs (Figure 
2B and Supplementary Table 4). The most common SCAA 
were deletion of either TP53 (N=4), CDKN2A (N=3), or 
APC (N=2) and amplification of AR (N=3) and MYC (N=2). 
Furthermore, bi-allelic loss of CDKN2A was observed in 
two patients (N=2). As previously mentioned, 18% (N=8) 
of the samples failed the analyses and 9% (N=4) were not 
analyzed due to limited cfDNA material (Figure 2B).
A SCAA was identified from either WES or 
OncoScan in 70% of the patients (31/44) involving all 
cancer types included in the study (Figure 3). This was 
lower than the overall CoPPO cohort (100%, Figure 1), 
however expectable from the type of input material. Whole 
exome sequencing lead to detection of SCAAs in 95% of 
the tissue biopsies compared to 88% and 45% in cfDNA 
from the pro-and retrospective cohorts, respectively 
(Figure 1). Adding the OncoScan SCNA analysis to the 
cfDNA profiling did not increase the number of positive 
findings in the prospective cohorts and only included one 
more patient (P35, prostate cancer with AR amplification) 
in the retrospective cohort.
Comparing genomic profiles identified by WES 
in plasma and tissue DNA
Fourteen re-biopsies and three archival FFPE 
samples were included in the study to compare the tumor 
Figure 1: Genomic profiling of the CoPPO cohort within the study period. A total number of 118 patients were included in the 
CoPPO project from January to 1st of August 2018. Eighteen patients were excluded because no plasma was collected for cfDNA analysis 
or tumor biopsies were pending. Tissue biopsies were usable for genomic profiling in 74 cases and a SCCA (selected cancer-associated 
aberrations) were identified in 95% and 100% of patients when using WES (whole exome sequencing) or WES+SCNA (somatic copy 
number alteration) analysis, respectively. The gray/red boxes indicate 26 patients with failed tissue biopsies either due to low tumor cell 
content (<10%, Cohort 2) or to inaccessible tumors (Cohort 1). Two patients were excluded; one due to lack of cfDNA and the other was 
included in Cohort 3 due prolonged start of the cfDNA-pipeline due to implementation of the setup in the laboratory. Twenty-four patients 
were prospectively profiled based on plasma cfDNA and a SCAA was identified using WES alone or plus SCNA analysis in 88% of the 
patients. In the retrospective cohort (gray/blue boxes) a SCAA was found in 45% using WES and in 50% when OncoScan analysis was 
included. N indicate the number of patients in each group.
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tissue to cfDNA (total N= 17). Nine of the sample-pairs 
were obtained in the prospective cohort. Two sample-
pairs could not be compared due to lack of detectable 
SCAAs (patient P38) and suboptimal quality of analysis 
(patient P18) and were excluded from the comparison 
(Supplementary Table 5). Shared SCAAs were observed 
in 73% (11/15) of patients from WES data. Private 
mutations were detected in 33% (5/15) and 67% (10/15) 
of plasma and tissue DNA samples, respectively (Table 2 
and Supplementary Table 5).
DISCUSSION
In this study, we show that genomic tumor profiling 
of cfDNA was feasible in all 44 patients compared to 
only 25% of patients who were eligible for re-biopsy. 
Plasma cfDNA profiling thus represents a minimally-
invasive alternative when tissue biopsies are not 
available. Especially, within the group of patients who 
cannot be biopsied, the benefit of applying cfDNA into 
cancer diagnostics is undoubtable. We successfully 
detected SCAAs in cfDNA in 8/9 patients in Cohort 
1 primarily being NSCLC and prostate cancers with 
inaccessible thoracic and bone metastases, respectively. 
In all prospective prostate cancer samples, a SCAA was 
identified mainly being amplification of the AR gene 
which is a well-known resistance mechanism in 50% of 
castration-resistant prostate cancers [20, 21]. In these 
cancer types, the use of cfDNA for tumor profiling is 
of great importance as a growing number of targeted 
therapies and clinical trials are available for different 
molecular subtypes of prostate and lung cancers [22–24]. 
None of the 24 prospectively analyzed patients had tumor 
alterations identified in cfDNA that were actionable by an 
open clinical trial or off-label program at our institution 
at the time of analysis. This was in line with the general 
CoPPO cohort in which only 20% of patients (101/500 
biopsied patients) received treatment based on tumor 
tissue profiling [25].
Figure 2: Selected cancer-associated alterations (SCAAs) identified in cfDNA. (A) WES was successfully performed on all 
cfDNA samples (N= 44). SCAAs were identified in 68% (30/44) of patients (+ SCAA). The most frequently altered genes were TP53, 
APC, KRAS, ATR, and PIK3CA. Furthermore, 30 different genes (NRAS, PIK3CG, BRAF, ATM, ARID1A, AKT2, FGF10, PCDHB12, 
ACIN1, RAD21, RAD51C, MYO6, SMARCA5, RAB14, FANCD2, CHD7, PTEN, AR, MAP3K9, WT1, POLR3B, MAP2K2, HDAC9, SOX9, 
MAP2K, SMAD4, RAD50, SMARCC2, CHEK1, IDH1) where mutated in only a single patient each, indicated by Other. Information on 
the individual alterations are included in Supplementary Table 3. (B) Analysis of somatic copy number alterations (SCNA) by OncoScan 
identified SCAAs in 30% of patients (13/44) most often involving deletion (D) or amplification (A) of TP53 (N= 4), CDKN2A (N= 3), AR 
(N= 3), MYC (N= 2), or APC (N= 2). Other included genes that were mutated in only a single patient being: CCND1 (A), KRAS (A), JAK2 
(A), MET (A), PTEN (bi-allelic). The bar plot, include only genes where a SCNA was identified together with a mutation in the same gene 
leading to both alleles affected. All SCNAs are reported in Supplementary Table 4. A silent chromosomal profile (- SCAA) was found in 
43% (19/44) of patients. The analysis failed in 18% (8/44) of the cases due to suboptimal quality of the cfDNA (N=1) or arrays (N=7). In 4 
cases (9%), the amount of cfDNA was insufficient for analysis.
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Despite a small sample size, this study indicates, 
that some cancer types might be more suitable for cfDNA 
profiling than others. Surprisingly, only 2/8 breast 
cancers had a SCAA identified by WES with mutation 
frequencies around 5%. None of the samples showed a 
positive finding on OncoScan, despite the high prevalence 
of SCNAs in breast cancers, often involving deletion of 
PIK3CA or amplification of ERBB2[26, 27]. These results 
could reflect a low fraction of plasma ctDNA in breast 
cancer patients that might be explained by the effect of 
active treatment at the time of plasma collection possibly 
increasing the level of normal cfDNA [28]. This was 
shown in a recent study of 210 patients with NSCLC, 
where ctDNA was detected in 43% of patients receiving 
systemic therapy at the time of plasma sampling and in 
75% of patient not in therapy [29]. Moreover, the low 
ctDNA detection might also be related to a small tumor 
burden known to correlate with both cfDNA and ctDNA 
levels [30, 31]. We have not correlated our findings with 
tumor burden due to limited access to radiological data 
at the time of plasma collection. Furthermore, we did 
not include baseline RECIST measurements as these 
underestimated the actual tumor burden due to exclusion 
of non-target lesions [32].
Analysis of cfDNA immediately following failed 
biopsy, markedly decreased the time to completed 
genomic reports (median 29 vs 60 days), a key factor 
for timely allocation of treatment in the Phase1 setting. 
Figure 3: OncoScan and WES results indicated by cancer type and active treatment (N=44). Identification of a selected 
cancer-associated alteration (SCAA) from either OncoScan or WES is indicated by +SCAA. Negative reports from WES (no SCAA, 
Supplementary Table 3) and Silent profiles, Failed, plus No analysis from OncoScan analyses (Supplementary Table 4) are indicated as 
-SCAA. Cancer types represented ≥3 times across cohorts, are color coded as shown in the legend. Gastrointestinal (GI) cancers included 
bile duct (N=3) and colorectal cancers (N=15). Cancer types “Other” included: Endometrial N=2, Gastric N =1, Ovarian N =1, Head and 
neck N =2, Mesothelioma N =1, Testicular N =1, Pancreatic N =1, Cervical N =1. Patients in active treatment at the time of plasma cfDNA 
collection are marked with a full-line border. Additional individual information is provided in Supplementary Table 1, 3, and 4.
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Even though, the time from failed biopsy until re-biopsy 
could be improved from the median 31 days observed 
here, cfDNA analysis would still be superior with 
respect to turnaround time. Furthermore, in some clinical 
settings, validation of potential treatment targets might be 
performed thus increasing the turnaround time concerning 
both tissue and cfDNA samples.
Despite all the advantages of cfDNA profiling, 
biopsy material remains the method of choice. The most 
obvious restriction of using cfDNA for genomic tumor 
profiling is the low tumor fraction (0.01–10%) in cfDNA 
[33, 34], in combination with the limited sensitivity of 
the current methods. OncoScan analysis only identified 
SCAAs in 13/44 patients most likely due to cfDNA 
input levels below the recommended 80 ng. In this small 
feasibility study, we could not assign any correlation 
between total cfDNA levels and the identification of 
ctDNA by either method (P>0.05). However, increased 
cfDNA levels might reflect a high degree of normal 
tissue destruction potentially diluting the ctDNA signal 
leading to false negative ctDNA results. In addition, the 
highly fragmented nature of cfDNA could also affect 
method efficacy. Solutions adjusted to small fragment 
DNA sizes are being developed [35], together with 
SCNA assays optimized for cfDNA [17]. Furthermore, it 
has been shown that increasing the cfDNA input to > 20 
ng for WES analysis improved the detection of ctDNA 
[19].
Another challenge of using cfDNA for oncological 
diagnostics, is the intrapersonal tumor evolution and 
hereby, a high degree of tumor heterogeneity. In this 
study, 65% of the SCAAs identified by WES was 
shared between plasma and tissue and private mutations 
were detected in 33% and 67% of plasma and tissue, 
respectively. However, large comparative studies are 
needed to assess the concordance between tumor and 
plasma biopsies and ongoing studies of postmortem 
samples like the PEACE study (NCT03004755) might 
help clarifying this aspect. Alterations in cfDNA have 
been suggested to represent clonal alterations rather than 
subclonal [18], possibly explaining the lower number of 
SCAAs private to cfDNA compared to tissue observed 
here. The lack of complete concordance between cfDNA 
and tissue likely reflects: 1) That the clonal nature of the 
tumor is not captured by a single biopsy; 2) That some 
tumor clones shed little DNA, or the frequency of the 
alteration was below the cut-off of 5%; Or 3) that the 
tumor evolves over time and in response to therapy, 
mainly important for the FFPE samples, representing 
archival material potentially years older than the cfDNA 
sample.
To our knowledge, this is the first study to test 
WES and SCNA analysis by OncoScan of cfDNA in a 
prospective trial. Previous studies have successfully used 
cfDNA for genomic profiling, but these studies have 
included only few patients [36] or not been clinically 
Table 2: Selected cancer-associated alterations (SCAAs) identified by WES in plasma and tissue DNA
Patient ID (cohort) Cancer subtype Shared SCAAs SCAAs in cfDNA SCAAs in tissue
P1 (2) Endometrial ATM, ARID1A, AKT2 ATM, ARID1A, AKT2 ATM, ARID1A, AKT2, RAD51C
P2 (2) Ovarian TP53 TP53, FGF10 TP53
P4 (2) Head and neck TP53, RAD21 TP53, RAD21
TP53, RAD21, 
PIK3CA, CDKN2A, 
RET
P6 (2) Pancreatic KRAS, TP53 KRAS, TP53, FANCD2 KRAS, TP53, ATR x2
P8 (2) Testicular SMARCA5, RAB14 SMARCA5, RAB14, MYO6
SMARCA5, RAB14, 
POLR3A
P9 (1) Prostate TP53 TP53 TP53
P13 (1)F Prostate PTEN PTEN, ATR PTEN
P23 (1)F Lung (NSCLC) KRAS KRAS, CHEK1 KRAS
P37 (3) Breast PIK3CA x2 PIK3CA x2 PIK3CA x2, TP53
P40 (3) Colorectal TP53 TP53 TP53, MET
P41 (3) Bile duct IDH1, ATR IDH1, ATR IDH1, ATR
Alterations identified by whole exome sequencing (WES) in patients with SCAAs identified in plasma and tissue DNA 
(N= 11). Patients where mutations were only identified in either cfDNA or tissue DNA are shown in Supplementary Table 5.
F FFPE material used for WES.
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relevant due to the high level of sequencing coverage and 
costs [37]. Our feasibility study was limited in sample 
size and heterogeneity of cancer types. Furthermore, we 
tested only WES and OncoScan as these methods were 
available in our clinical setting. Indications related to 
the effect of cancer type and active therapy on cfDNA 
profiling needs further validation in larger and uniform 
cohorts.
In conclusion, genomic tumor profiling using 
plasma cfDNA constitutes an alternative when tissue 
biopsies are unavailable. Especially, WES identified 
SCAAs and potential treatment targets whereas SCNA 
analysis by OncoScan needs optimization for cfDNA. 
Advanced prostate and lung cancer patients can 
particularly benefit from cfDNA profiling contrary to 
breast cancers, where preselection based on treatment 
status should be considered. Finally, more SCAAs were 
identified in fresh tumor tissue highlighting that tissue is 
still the preferable material for genomic profiling due to 
the higher density of tumor DNA.
MATERIALS AND METHODS
Patients
Patients with metastatic solid tumors were recruited 
to the Phase I Unit at Rigshospitalet, Department 
of Oncology, Copenhagen University, as part of the 
Copenhagen Prospective Personalized Oncology study 
(CoPPO) project (NCT02290522)[25]. The study was 
conducted in accordance with the Declaration of Helsinki 
and written informed consent was obtained for all patients 
(Danish Ethical Committee, file number: 1300530). We 
included three cohorts: 1) A prospective cohort (Cohort 
1; N=9) including patients with tumors inaccessible 
for biopsy due to location e.g. bone metastasis only, 
inaccessible thoracic lesions etc.; 2) A prospective cohort 
(Cohort 2; N=15) including patients whose initial tissue 
biopsy failed the genomic analyses due to low levels of 
tumor cells (<10%); 3) A retrospective cohort (Cohort 3; 
N=20), consisting of patients whose initial biopsy failed 
and was unusable for genomic profiling. The inclusion 
period for Cohort 1 and 2 was from January to 1st of 
August 2018.
DNA collection and purification
Two blood samples were collected from each patient, 
one for germline DNA (gDNA) analysis as described 
for the CoPPO study [25] and one for cfDNA analysis. 
Peripheral blood for cfDNA analysis was collected in cell-
stabilizing BCT-tubes (Streck Laboratories) as previously 
described [38] and extracted from 4 ml plasma using the 
QIAsymphony Circulating DNA Kit (Qiagen) according 
to the manufacturer's instructions using an elution volume 
of 60 μl. Extracted cfDNA was quantified using a dsDNA 
HS Assay Kit on a Qubit Fluorometer (Thermo Fisher 
Scientific) and subsequently stored at -20°C until further 
use. For patients with a successful re-biopsy, fresh tumor 
tissue was collected in RNA-later as part of the CoPPO 
project. Archival FFPE tissue was included if available 
and DNA was extracted using the Gene Read DNA FFPE 
Kit (Qiagen).
Genomic profiling
DNA libraries were prepared from 10 ng cfDNA 
or FFPE-DNA using the NEBNext Ultra II protocol 
(New England Biolabs) and hybridized using the 
MedExome capture panel (Roche) or Agilent SureSelect 
system, respectively. DNA libraries from gDNA or 
fresh tissue re-biopsies were generated from 500 ng 
DNA using SureSelect (Agilent). All DNA libraries 
enriched for exonic sequences were then quantified and 
quality-controlled using a Qubit HS flourometer and 
the TapeStation 4200 High Sensitivity assay (Agilent). 
Finally, all libraries were sequenced as paired-end on the 
NextSeq or HiSeq sequencer (Illumina). Plasma cfDNA 
libraries were sequenced with an average coverage >100x 
(Supplementary Figure 2).
Sequencing reads were mapped to the hg19/
GRCh37 reference genome using the CLC Workbench 
v.3.5.4. Tumor-specific variants were identified by 
excluding germline variants and requiring a variant to 
have 1) ≥ 10x coverage; 2) forward/reverse balance ≥ 
0.1; (3) tumor variant frequency ≥ 5%. Variants were 
identified using the Ingenuity Variant Analysis Software 
(Qiagen) and selected cancer-associated alterations 
(SCAAs) were manually inspected and included in the 
final genomic reports comprising: 1) Previously reported 
cancer variants described in COSMIC [39], Ingenuity 
Knowledge database (Qiagen) or in published literature 
and 2) novel truncating alterations in tumor suppressor 
genes or missense alterations in known oncogenes 
predicted by in silico analysis [40] to be affecting protein 
function. The SCAA definition thus included class I to 
III variants according to the Tier classification [41]. The 
analysis excluded low quality and common variants (>1% 
in the Exome Aggregation Consortium database (ExAC), 
1000 Genomes Project or NHLBI Exome sequencing 
project (ESP)) and included non-synonymous alterations 
as well as splice site alterations +/- 2bp from exon/intron 
boundaries.
Somatic copy number alterations (SCNA) 
were analysed using the OncoScan CNV Plus assay 
(ThermoFisher Scientific) with minimum input of 5 ng 
cfDNA. The data was visually inspected and analysed 
using the Nexus Software v 8.0 (BioDiscovery). The 
analysis of SCNAs focused on detection of amplification 
(copy number >5), bi-allelic losses, deletions, and loss of 
heterozygosity (LOH). On fresh tissue re-biopsies, SCNAs 
were analyzed using CytoScanHD assay (Affymetrix) 
Oncotarget1396www.oncotarget.com
with DNA input of 250 ng according to the manufactures 
instructions. Sensitivity of the applied methods were 5% 
and 20–30% for WES and OncoScan, respectively. Hence 
a negative report does not necessarily indicate lack of 
tumor specific alterations or ctDNA.
Statistical analyses
A t-test was used to test, whether cfDNA 
concentration or DNA input affected the results from 
OncoScan analysis. Due to small sample sizes, Fishers-
exact test was performed to compare the number of breast 
cancer patients harboring a SCAA to those with no SCAA. 
A P-value <0.05 was considered statistically significant. 
Furthermore, descriptive statistics were used, including 
medians, ranges, and frequencies. All statistical analyses 
were done in R (version 0.99.903).
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